title: Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy.
abstract: OBJECTIVE
  To compare the efficacy of adjuvant chemotherapy after radical hysterectomy with that of adjuvant radiotherapy.
  
  
  METHODS
  One hundred one women with invasive cervical carcinoma (stage IB through early stage IIB) underwent radical hysterectomy at Saga Medical School Hospital. Of these patients, 53 with squamous or adenosquamous carcinoma were classified as high risk, based on the presence of one or more of the following high-risk factors for recurrence: 1) lymph node metastasis, 2) deep cervical stromal invasion (greater than 3/4 thickness), and 3) parametrial invasion. Adjuvant chemotherapy with a combination of cis-diamminedichloroplatinum (CDDP), vincristine, mitomycin C, and peplomycin (POMP), was prescribed. The outcome was compared with that for 127 patients who were classified as high risk under the same criteria and who received adjuvant radiotherapy at Kyushu University Hospital.
  
  
  RESULTS
  The 5-year survival rates were much the same: 83.0% for adjuvant chemotherapy and 81.7% for adjuvant radiotherapy. In the chemotherapy group, intra- and extrapelvic recurrences accounted for 85 and 23% of all recurrences, respectively, whereas recurrences were noted for 38 and 71% in the radiotherapy group, respectively (P < .01).
  
  
  CONCLUSIONS
  The use of adjuvant chemotherapy reduces extrapelvic recurrences. The combination of both adjuvant therapies may improve the prognosis for high-risk patients.
authors.affiliation: Department of Obstetrics and Gynecology, Saga Medical School, Japan. iwasaka@post.saga-med.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Iwasaka
authors.forename: T
authors.initials: T
authors.lastname: Kamura
authors.forename: M
authors.initials: M
authors.lastname: Yokoyama
authors.forename: N
authors.initials: N
authors.lastname: Matsuo
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: H
authors.initials: H
authors.lastname: Sugimori
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018196:Carcinoma, Adenosquamous / Q000401:mortality / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D017663:Peplomycin / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D011882:Radiotherapy, High-Energy; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016685:Mitomycin; D017663:Peplomycin; D014750:Vincristine; D002945:Cisplatin